ClinicalTrials.gg
CompletedNCT06619678Updated Nov 10, 2026

A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

A Phase 1 interventional study of MK-8507 and Islatravir in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Jan 2024, registered Sep 2024).
Updated Nov 10, 2026Results publication addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
19 Years to 65 Years
Sex
All
01

Study summary

The main goals of this study are to learn what happens to Islatravir or MK-8507 in a person's body over time. Researchers will compare Islatravir given alone to Islatravir given with MK-8507. Researchers will also compare MK-8507 given alone to MK-8507 given with Islatravir.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a (BMI) ≥18 and ≤32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer with protocol specified exceptions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Islatravir+MK-8507

    Period 1: Participants receive single dose of Islatravir on Day 1. Period 2: Participants receive single dose of MK-8507 on Days 1 and Days 8. Period 3: Participants receive single dose of Islatravir and single dose of MK-8507 on Day 1, 7 days after the Day 8 dose of MK-8507, during Period 2. Participants will receive additional MK-8507 single doses on Days 8, 15, 22, and 29.

    Drug: MK-8507 · Drug: Islatravir

Interventions

  • Oral administration

  • Oral administration

    Also known as: ISL, MK-8591

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Islatravir Metabolite

    Blood samples will be collected to determine the AUC0-Inf of Islatravir metabolite.

    Time frame: At designated timepoints (up to approximately 43 days)

  2. Area Under the Concentration-Time Curve from Time 0 to 168 hours (AUC0-168hrs) of Islatravir Metabolite

    Blood samples will be collected to determine the AUC0-168hrs of Islatravir metabolite.

    Time frame: At designated timepoints (up to approximately 168 hours)

  3. Maximum Concentration (Cmax) of Islatravir Metabolite

    Blood samples will be collected to determine Cmax of Islatravir metabolite.

    Time frame: At designated timepoints (up to approximately 43 days)

  4. Plasma Concentration at 168 Hours (C168) of Islatravir Metabolite

    Blood samples will be collected to determine the C168 of Islatravir metabolite.

    Time frame: At designated timepoints (up to approximately 168 hours)

  5. Time to Maximum Concentration (Tmax) of Islatravir Metabolite

    Blood samples will be collected to determine the Tmax of Islatravir metabolite.

    Time frame: At designated timepoints (up to approximately 43 days)

  6. Apparent Terminal Half-life (t1/2) of Islatravir Metabolite

    Blood samples will be collected to determine the t1/2 of Islatravir metabolite.

    Time frame: At designated timepoints (up to approximately 43 days)

  7. AUC0-Inf of Islatravir

    Blood samples will be collected to determine the AUC0-Inf of Islatravir.

    Time frame: At designated timepoints (up to approximately 22 days)

  8. AUC0-168hrs of Islatravir

    Blood samples will be collected to determine the AUC0-168hrs of Islatravir.

    Time frame: At designated timepoints (up to approximately 7 days)

  9. Cmax of Islatravir

    Blood samples will be collected to determine Cmax of Islatravir.

    Time frame: At designated timepoints (up to approximately 22 days)

  10. C168 of Islatravir

    Blood samples will be collected to determine the C168 of Islatravir.

    Time frame: At designated timepoints (up to approximately 168 hours)

  11. Tmax of Islatravir

    Blood samples will be collected to determine the Tmax of Islatravir.

    Time frame: At designated timepoints (up to approximately 22 days)

  12. t1/2 of Islatravir

    Blood samples will be collected to determine the t1/2 of Islatravir.

    Time frame: At designated timepoints (up to approximately 22 days)

  13. Apparent clearance (CL/F) of Islatravir

    Blood samples will be collected to determine the CL/F of Islatravir.

    Time frame: At designated timepoints (up to approximately 22 days)

  14. Apparent Volume of Distribution During Terminal Phase (Vd/F) of Islatravir

    Blood samples will be collected to determine the Vd/F of Islatravir.

    Time frame: At designated timepoints (up to approximately 22 days)

  15. AUC0-168hrs of MK-8507

    Blood samples will be collected to determine the AUC0-168hrs of MK-8507.

    Time frame: At designated timepoints (up to approximately 7 days)

  16. Cmax of MK-8507

    Blood samples will be collected to determine Cmax of MK-8507.

    Time frame: At designated timepoints (up to approximately 15 days)

  17. C168 of MK-8507

    Blood samples will be collected to determine the C168 of MK-8507.

    Time frame: At designated timepoints (up to approximately 168 hours)

  18. Tmax of MK-8507

    Blood samples will be collected to determine the Tmax of MK-8507.

    Time frame: At designated timepoints (up to approximately 15 days)

  19. t1/2 of MK-8507

    Blood samples will be collected to determine the t1/2 of MK-8507.

    Time frame: At designated timepoints (up to approximately 15 days)

  20. CL/F of MK-8507

    Blood samples will be collected to determine the CL/F of MK-8507.

    Time frame: At designated timepoints (up to approximately 15 days)

  21. Vd/F of MK-8507

    Blood samples will be collected to determine the Vd/F of MK-8507.

    Time frame: At designated timepoints (up to approximately 15 days)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 5 months

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 5 months

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Publications

  • Nussbaum JC, Pham MM, Vargo R, Liu Y, Triantafyllou I, Boyette N, Matthews RP, Iwamoto M, Gillespie G. Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV. Antimicrob Agents Chemother. 2026 Nov 4;70(11):e0067626. doi: 10.1128/aac.00676-26. Epub 2026 Oct 8. PubMed 42847999 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jun 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Oct 1, 2024
StartActual
Jan 17, 2024
Primary completionActual
Jun 23, 2024
CompletionActual
Jun 23, 2024
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
Results publication added: Nussbaum JC, Pham MM, Vargo R, Liu Y, Triantafyllou I, Boyette N, Matthews RP, Iwamoto M, Gillespie G. Open-label Phase 1 study to evaluate drug-drug interacti… PubMed 42847999 ↗
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Publications Results publication added: Nussbaum JC, Pham MM, Vargo R, Liu Y, Triantafyllou I, Boyette N, Matthews RP, Iwamoto M, Gillespie G. Open-label Phase 1 study to evaluate drug-drug interacti… PubMed 42847999 ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06619678
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Jan 17, 2024
Primary completion
Jun 23, 2024
Completion
Jun 23, 2024
Last update
Nov 10, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ulonivirine · Islatravir

Start the discussion